Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AYP-101 in submental fat reduction
NCT05476094Phase 1Completed
- Sponsor
- AMIpharm
- Start
- Aug 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of polyene phosphatidylcholine in submental fat (3 arms), sponsored by AMIpharm. Primary endpoint: Number and Incidence of Adverse Events at 28 days. Started Aug 2022; status: completed.
02
Drugs
polyene phosphatidylcholine
03
Conditions
submental fat
Beyond the preview
Go deeper on NCT05476094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05476094.